Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.88 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.88 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.88 |
| ▸ | RXRA | P19793 | 3/20 | 0.74 |
| ▸ | HMGCR | P04035 | 3/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.44 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.44 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | CCKAR | P32238 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.44 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8319507 | 1.00 | NR4A2 (0.88) | NR4A2PDE4DNR1I2RXRAHMGCR | |
| SCHEMBL4422434 | 1.00 | NR4A2 (0.88) | NR4A2PDE4DNR1I2RXRAHMGCR | |
| SCHEMBL4425767 | 0.94 | NR4A2 (0.85) | NR4A2PDE4DNR1I2RXRAHMGCR | |
| SCHEMBL4425758 | 0.94 | NR4A2 (0.85) | NR4A2PDE4DNR1I2RXRAHMGCR | |
| Pitavastatin SCHEMBL2878736 | 0.93 | PDE4D (1.00) | NR4A2PDE4DNR1I2RXRAHMGCR | |
| Pitavastatin SCHEMBL6068293 | 0.93 | PDE4D (1.00) | NR4A2PDE4DNR1I2RXRAHMGCR | |
| Pitavastatin SCHEMBL2878734 | 0.93 | PDE4D (1.00) | NR4A2PDE4DNR1I2RXRAHMGCR | |
| Pitavastatin SCHEMBL13278902 | 0.93 | PDE4D (1.00) | NR4A2PDE4DNR1I2RXRAHMGCR | |
| Pitavastatin SCHEMBL2878610 | 0.93 | PDE4D (1.00) | NR4A2PDE4DNR1I2RXRAHMGCR | |
| Pitavastatin SCHEMBL13278896 | 0.93 | PDE4D (1.00) | NR4A2PDE4DNR1I2RXRAHMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005023305-A2 | MODULATING CELL ACTIVITY BY USING AN AGENT THAT REDUCES THE LEVEL OF CHOLESTEROL WITHIN A CELL | INPHARMATICA LIMITED (GB) | 2005-03-17 | — | — | WO | claimed |
| US-9034901-B2 | Pitavastatin calcium and process for its preparation | CADILA HEALTHCARE LIMITED (IN) | 2015-05-19 | — | — | US | disclosed |
| US-20140148481-A1 | PITAVASTATIN CALCIUM AND PROCESS FOR ITS PREPARATION | CADILA HEALTHCARE LIMITED (IN) | 2014-05-29 | — | — | US | disclosed |
| US-8487105-B2 | Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof | MSN LABORATORIES LIMITED (IN) | 2013-07-16 | — | — | US | disclosed |
| US-8487105-B2 | Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof | MSN LABORATORIES LIMITED (IN) | 2013-07-16 | — | — | US | disclosed |
| US-20120016129-A1 | Process for Preparing Pitavastatin, Intermediates and Pharmaceuctically Acceptable Salts Thereof | MSN LABORATORIES LIMITED (IN) | 2012-01-19 | — | — | US | disclosed |
| US-20120016129-A1 | Process for Preparing Pitavastatin, Intermediates and Pharmaceuctically Acceptable Salts Thereof | MSN LABORATORIES LIMITED (IN) | 2012-01-19 | — | — | US | disclosed |
| US-20090186834-A1 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | MICROBIA, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090005321-A1 | Phenylazetidinone Derivatives | MICROBIA, INC. (US) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016129-A1 | Process for Preparing Pitavastatin, Intermediates and Pharmaceuctically Acceptable Salts Thereof | PCSK9, HMGCR, HDLBP | NR4A2 3911/4885PDE4D 579/4885NR1I2 3388/4885 |
| US-20090186834-A1 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | NPC1L1, CYP46A1, NPC1 | NR4A2 1217/4885PDE4D 453/4885NR1I2 114/4885 |
| US-20140148481-A1 | PITAVASTATIN CALCIUM AND PROCESS FOR ITS PREPARATION | ATG4A, CTSC, CA4 | NR4A2 4048/4885PDE4D 365/4885NR1I2 4521/4885 |
| US-20090005321-A1 | Phenylazetidinone Derivatives | TYR, AAAS, FANCD2 | NR4A2 2746/4885PDE4D 655/4885NR1I2 1769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.